The World Health Organization (WHO) has issued a global alert over four cough syrups, warned they could be linked to the deaths of 66 children in The Gambia.
The Organisation stated that; the syrup is “potentially linked with acute kidney injuries and 66 deaths among children”.
The products were manufactured by an Indian company, Maiden Pharmaceuticals, which had failed to provide guarantees about their safety, the WHO added.
The WHO identified the medicines as Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup and Magrip N Cold Syrup.
The four products had been identified in The Gambia, but “may have been distributed, through informal markets, to other countries or regions”, the WHO added, in the alert published on its website.
It warned that their use may result in serious injury or death, especially among children.
According to BBC, The WHO’s intervention came after medical authorities in The Gambia – a popular tourist destination – detected an increase in cases of acute kidney injury among children under the age of five in late July.
The Gambia’s government has since suspended the use of all paracetamol syrups and has urged people to use tablets instead.
The number of deaths has declined since the ban but two more have been recorded in the past two weeks, Gambia health services director Mustapha Bittay told the BBC’s Focus on Africa programme.
He said that The Gambia did not currently have a laboratory capable of testing whether medicines were safe and so they had to be sent abroad for checking. Mr Bittay added that The Gambia was in discussions with the World Bank to get funding for a quality-control laboratory.
The WHO said that laboratory analysis of samples of the products “confirms that they contain unacceptable amounts of diethylene glycol and ethylene glycol as contaminants”.
The substances were toxic, and their effects “can include abdominal pain, vomiting, diarrhoea, inability to pass urine, headache, altered mental state and acute kidney injury which may lead to death,” it added.
The WHO said that India’s Central Drugs Standard Control Organisation indicated that the manufacturer may have only supplied the contaminated medications to The Gambia, AFP news agency reports, quoting an email from the UN health agency.